Maestros Medi. (501209)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Reported ROE of 17.67%, if accurate, suggests some positive equity-level metric.
• Company is publicly listed, providing a transparent platform and access to capital markets.
• Latest quarterly net loss is small at ₹1 Cr, so near-term cash burn appears limited.
• A ₹2,976 Cr market cap ensures visible trading interest, though valuation remains extreme.

Concerns

• Sales growth of -45.69% and profit growth of -163.57% show a shrinking, loss-making business.
• ROCE of -19.11% indicates capital employed is earning negative returns, pointing to no moat.
• P/E of 0.00, zero dividend, and a latest quarter net loss leave no fundamental earnings support.
• Piotroski F-Score of 2/9 signals weak financial health and elevated risk of further distress.

AI Analysis

Let me ask what Graham would ask: Is this a business I understand, and does it earn a decent return on capital? At ₹10.44, Maestros Medi carries a market cap of ₹2,976 Cr. Yet the latest quarter shows only ₹1 Cr of sales and a ₹1 Cr net loss. That is a giant red flag. Sales have collapsed 45.69%, and profit growth is -163.57%. A P/E of 0.00 confirms there are no sustainable earnings to value. ROCE is -19.11%, so capital employed is being destroyed. The positive ROE of 17.67% looks like an accounting artifact of a tiny equity base, not franchise strength. The Piotroski F-Score of 2/9 reinforces this: poor profitability, weak operations, and deteriorating fundamentals. Dividend yield is zero, so there is no income support while waiting. In Graham's terms, I demand a margin of safety. Here there is none. A ₹2,976 Cr market cap against quarterly sales of ₹1 Cr prices in extraordinary future growth with no evidence of ability to execute. This is not an investment; it is a speculation. The wise path is to watch from the sidelines. Unless there is clear evidence of a credible turnaround—new management, a visible path to positive operating margins, and a sane valuation—this belongs in the 'too hard' pile. I would rather miss the trade than lose my capital.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer